Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29054023 | 0.88 | MME (0.46) | TAAR1HTR2AAOC3MMEHRH1 | |
| SCHEMBL29002686 | 0.84 | TAAR1 (0.54) | TAAR1HTR2AAOC3MMEHRH1 | |
| SCHEMBL3646327 | 0.84 | TAAR1 (0.48) | TAAR1HTR2AAOC3HRH1CHRNB2 | |
| SCHEMBL18863922 | 0.81 | MME (0.42) | TAAR1HTR2AAOC3MMEHRH1 | |
| SCHEMBL28218195 | 0.78 | MME (0.43) | TAAR1HTR2AAOC3MMEHRH1 | |
| SCHEMBL1936284 | 0.78 | MME (0.40) | TAAR1AOC3MMELMNA | |
| SCHEMBL26720658 | 0.77 | SLC7A5 (0.50) | TAAR1HTR2AHRH1LMNA | |
| SCHEMBL7692329 | 0.74 | TAAR1 (0.56) | TAAR1HTR2AAOC3LMNA | |
| SCHEMBL1985899 | 0.74 | GABBR2 (0.52) | TAAR1HTR2AAOC3HRH1CHRNB2 | |
| SCHEMBL10581707 | 0.74 | TAAR1 (0.56) | TAAR1HTR2AAOC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | OLIPASS CORPORATION (KR) | 2019-11-07 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
| EP-0424965-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| US-4960934-A | Amine oxide process | ETHYL CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| US-4942260-A | REACTION OF A TERT-AMINE WITH HYDROGEN PEROXIDE IN THE PRESENCE OF CATALYTIC CARBON DIOXIDE | ETHYL CORPORATION (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0356918-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4889954-A | DIALKYLCARBONATE CATALYST | ETHYL CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0307184-A2 | Preparation of Amine Oxides | ETHYL CORPORATION (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | TAAR1 1900/4885HTR2A 1606/4885AOC3 4367/4885 |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | PTBP1, RBM17, UPF1 | TAAR1 4470/4885HTR2A 4665/4885AOC3 4867/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | TAAR1 3403/4885HTR2A 2578/4885AOC3 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.